Repellent Transcranial Magnetic Stimulation Improves Depressive Symptoms and Quality of Life of Poststroke Patients—Prospective Case Series Study

Hercílio Barbosa da Silva Júnior, Marcos Rassi Fernandes, and Ângela Maria Costa Souza

BACKGROUND: Poststroke depression (PSD) is a serious psychiatric complication often reported after a stroke. Nearly a third of stroke survivors experience depressive symptoms at some point, affecting their functional recovery and quality of life. In recent years, repetitive transcranial magnetic stimulation (rTMS) has been studied by many researchers and found to be a safe supporting tool for the treatment of PSD.

OBJECTIVE: We aim to evaluate the effects of rTMS on PSD and on the quality of life of poststroke patients.

METHOD: A prospective clinical case series, performed at CRER Rehabilitation, Brazil, between June 2016 and May 2017. A nonprobabilistic sample (n = 15) was divided into 2 groups (excitatory stimulation in F3, n = 8; inhibitory stimulation in F4, n = 7) and underwent 20 sessions of rTMS. Individuals were assessed according to the 17-item Hamilton Depression Rating Scale (HAM-D17) and World Health Organization Quality of Life-Brief Version (WHOQOL-BREF) questionnaire at 3 different moments: baseline, at the end of the treatment, and in a 1-month follow-up meeting.

RESULTS: Both groups presented a significant change in the score of all WHOQOL-BREF domains and in HAM-D17. In the group that received inhibitory stimulation (F4), score changes were continuous and gradual, comparing the 3 moments. In the excitatory stimulated (F3) group, however, the improvement in scores was more expressive between baseline and the second moment, without significant changes in the follow-up.

CONCLUSIONS: The findings of this clinical study suggest that rTMS can be a promising tool, capable of relieving depressive symptoms and helping in the improvement of poststroke patients’ quality of life.

KEYWORDS: Transcranial magnetic stimulation, depression, stroke, quality of life

Introduction

Poststroke depression (PSD) is a psychiatric complication that occurs in nearly one-third of the cases of stroke survivors, eventually affecting their functional recovery and quality of life. Poststroke depression may be associated with increased physical disabilities, cognitive and social impairment, poorer outcome in motor rehabilitation, poor quality of life, and increased risk of recurrence of stroke or suicide.

Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are indicated as the primary therapeutic intervention, even though their benefits are not expressive in PSD remission. In addition to that, recent studies have shown that the use of tricyclic antidepressants (ADTs) and SSRIs may increase the risk of stroke recurrence in some patients.

In 2008, the Food and Drug Administration of the US Health and Human Services Department approved repetitive transcranial magnetic stimulation (rTMS) as a safe tool for the treatment of depression in patients who have not found relief from antidepressant medication. Regarding PSD, some significant evidence of the effectiveness of rTMS has been reported but further studies are required to validate protocols.

The rTMS is a noninvasive neuromodulation and neurostimulation technique capable of modulating excitability between the cerebral hemispheres. Among its benefits, rTMS is relatively painless, noninvasive, simple to apply, and presents low risk for research with human beings. Barker and his team demonstrated this technique for the first time in 1985, in Sheffield, England. Since its discovery, scientists around the world are studying rTMS effects for treatment in psychiatry, neurology, and perhaps other clinical specialties, such as depression. Depending on the frequency—measured in Hertz—rTMS can result in inhibitory or excitatory effects. The low-frequency rTMS (⩽1 Hz) is commonly used to decrease cortical excitability, whereas the high-frequency rTMS (⩾5 Hz) is used to stimulate it.
In this study, we applied and compared 2 different protocols using high- or low-frequency rTMS depending on the location of the brain lesion. Our aim was to evaluate the effects of rTMS on PSD symptoms and its impact on the quality of life of poststroke patients.

Methods
This was a prospective clinical case series, performed at the Neuromodulation Laboratory of the Dr. Henrique Santillo State Rehabilitation Centre (CRER), in the state of Goiás, Brazil, from June 2016 to May 2017.

Charts review and patients’ selection
The charts review included patients registered on the internal management system of CRER. All patients registered to the system were previously assessed by the multidisciplinary staff and then referred to the waiting list of the proper care department. To find the subjects of this study who would undergo treatment for depression using rTMS, we looked for the charts of those who were waiting for psychiatric outpatient treatment.

We searched through the system using the keywords “depression” and “stroke.” Among these patients, we recruited the ones (a) with a history of stroke either in the right or left hemispheres, (b) at least 6 months past the stroke episode, (c) confirmed by nuclear magnetic resonance, (d) aged between 21 and 80 years, (e) diagnosed with Major Depression Disorder according to Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-V) criteria, and (f) with absence of severe cognitive dysfunction or aphasia.

We considered patients those who (a) scored ≤18 on the 17-item Hamilton Depression Rating Scale (HAM-D17), (b) were already on outpatient therapy at any other department of CRER, (c) had other psychiatric or neurological disease associated with stroke, (d) had a history of epilepsy, (e) had any metal in their skull or a cardiac pacemaker, (f) had a history of depression before stroke, and (g) underwent previous treatment with rTMS as ineligible for the study.

The rTMS intervention was discontinued for patients who (b) presented nontolerance to the stimulation side effects and (i) attended less than 75% of the treatment program sessions.

Clinical assessments
After the charts review, all preselected patients underwent a more detailed clinical evaluation by a neuropsychologist prior to the first day of treatment. They were interviewed about their medical records, considering the selection criteria of this study. They were offered a treatment with rTMS, and after receiving a full explanation of the study and its procedures, the selected patients, who met all the inclusion criteria, signed a written informed consent statement approved by the ethics committee.

All selected subjects for this study were assessed at baseline, at the end of the treatment, and during a follow-up meeting 1 month following the treatment. Poststroke depression was measured using HAM-D17, which was applied as an interview. The instrument evaluates the intensity of depressive symptoms, meaning that the higher the score, the greater the level of depression. Response to the treatment was considered if there was an improvement in at least 13 points from the baseline score. Remission was considered for scores ≤7. The patients’ quality of life was measured using the WHOQOL-BREF questionnaire. This instrument’s score ranges from 0 to 100, meaning that the higher the score, the better the patient’s quality of life level. WHOQOL-BREF was applied as a self-administered questionnaire.

In this series, baseline HAM-D17 and WHOQOL-BREF scores were used as the primary outcome measure. The following assessment scores (end of treatment and follow-up) were used as secondary outcomes measurement.

The rTMS procedures
The rTMS was delivered using a high-speed magnetic neuro stimulator (Neurosoft Company, Neuro/MS, Russia) equipped with a figure-8-shaped coil and intermittent cooling. The protocol consisted of 20 rTMS sessions, each one lasting 20 minutes. The protocol was ministered by the physician responsible for the neuromodulation laboratory of CRER for 4 weeks (1 session per business day).

The nonprobabilistic sample was divided into 2 groups with different treatment frequencies (Figure 1), excitatory (10 Hz), or inhibitory (1 Hz), according to the location of the injury. When the patient’s lesion was located in F3—left dorsolateral prefrontal cortex (DLPFC)—or in regions near that target, we applied the low-frequency protocol (inhibitory), with 1 Hz on F4—the right DLPFC—using 80% to 90% of the motor threshold.

Figure 1. (A) The rTMS excitatory protocol—10 Hz on the left DLPFC (F3) using 100% to 110% of motor threshold—20 minutes session: 40 trains, 50 pulses per train, 2000 pulses in total. (B) The rTMS inhibitory protocol—1 Hz on the right DLPFC (F4) using 80% to 90% of motor threshold—20 minutes session: 1 stimulus per second (1200 pulses in total). DLPFC indicates dorsolateral prefrontal cortex; rTMS, repetitive transcranial magnetic stimulation.
of children—none/1 or 2, and (f) type of intervention—
for psychiatric outpatient treatment. After analyzing their
system retrieved a list of 1080 individuals on the waiting list
searched for the keywords “depression” and “stroke.” The
Using the internal management system of CRER, we
Results
HAM-D score was performed based on the
(HAM-D) scores. The clinical status comparison with the
ators indicated significant differences—was used for comparing
and after the intervention, the Friedman test followed by the
consistency of the instrument for the studied sample. Before
) to verify the internal
deviation and median/interquartile range for continuous vari-
tives. We applied nonparametric statistical tests, considering
the data set conditions (assumptions) which were not sufficient
for an eventual use of parametric tests, such as Shapiro-Wilk
test for normality, for example.

The reliability of the WHOQOL-BREF questionnaire was
tested by Cronbach alpha coefficient (α) to verify the internal
consistency of the instrument for the studied sample. Before
and after the intervention, the Friedman test followed by the
Wilcoxon test—represented by letters, in which different let-
ters indicated significant differences—was used for comparing
the quality of life and Hamilton Depression Rating Scale
(HAM-D) scores. The clinical status comparison with the
HAM-D score was performed based on the χ² test. The level
of significance was 5%.

Regarding the ethical aspects, the Research Ethics
Committee of the Federal University of Goiás approved
our study under the following protocol number: CAAE
50623315.3.0000.5083. This study was also in compliance
with Resolution 466 of the Helsinki Treaty, and all participants
signed a free and clarified term of consent.

Statistical Analysis
The software used to analyze all collected data was Statistical
Package of Social Sciences (SPSS 23.0). General characteris-
tics of the group were presented by means of absolute and rela-
tive frequency for qualitative variables and mean/standard
deviation and median/interquartile range for continuous vari-
ables. We applied nonparametric statistical tests, considering
the data set conditions (assumptions) which were not sufficient
for an eventual use of parametric tests, such as Shapiro-Wilk
test for normality, for example.

The reliability of the WHOQOL-BREF questionnaire was
tested by Cronbach alpha coefficient (α) to verify the internal
consistency of the instrument for the studied sample. Before
and after the intervention, the Friedman test followed by the
Wilcoxon test—represented by letters, in which different let-
ters indicated significant differences—was used for comparing
the quality of life and Hamilton Depression Rating Scale
(HAM-D) scores. The clinical status comparison with the
HAM-D score was performed based on the χ² test. The level
of significance was 5%.

Regarding the ethical aspects, the Research Ethics
Committee of the Federal University of Goiás approved
our study under the following protocol number: CAAE
50623315.3.0000.5083. This study was also in compliance
with Resolution 466 of the Helsinki Treaty, and all participants
signed a free and clarified term of consent.

Results
Using the internal management system of CRER, we
searched for the keywords “depression” and “stroke.” The
system retrieved a list of 1080 individuals on the waiting list
for psychiatric outpatient treatment. After analyzing their
charts, we excluded 1040 who did not meet the selection
criteria for the study. The 40 preselected candidates were
called for a detailed pretreatment clinical evaluation. From
these interviews, 20 individuals were also excluded due to
the selection criteria and 20 were eligible to undergo the
treatment with rTMS. Of them, 5 patients did not adhere to
the treatment, being absent for more than 2 sessions in a
row or more than 5 sessions during the whole process. Thus,
15 individuals completed the treatment procedures. The
only reported side effect during the course of the rTMS
experiment was a transient headache.

Table 1 lists the demographic and clinical profile of the
patients, as well as the type of protocol used, whether inhibi-
tory or excitatory. Most of the participants were adults and only
5 were older than 65 years of age (elderly). The intervention
was homogeneous in relation to the sample data.

Figure 2 compares the mean/standard deviation and mini-
imum/maximum values of HAM-D17 scores before and after
the intervention with rTMS. There was a significant difference
between the scores of baseline (min = 20; max = 31; mean:
24.60 ± 3.27) and the assessment at the end of the treatment
(min = 3; max = 9; mean: 5.27 ± 1.79) and also between the
scores of baseline and the 1-month follow-up assessment
(min = 3; max = 6; mean: 4.33 ± 0.82). There was no significant
difference when comparing the score at the end of the treat-
ment and at the 1-month follow-up.

Figure 3 compares the quality of life evaluation at the 3
moments (baseline, end of treatment, and 1-month follow-up).
There was a significant improvement in all WHOQOL-
BREF domain scores. The psychological domain scores showed
a greater difference in mean values after the intervention. At
baseline, the psychological domain score was 28.34 ± 19.05; at
the end of the treatment, it increased to 63.34 ± 9.74; and in
the follow-up assessment 1 month after the treatment, it
changed to 71.95 ± 9.12.

Table 2 presents the comparison of HAM-D17 scores
before and after rTMS intervention. At the baseline, 73.3% of
the patients had very severe depression (score ≥ 23); at the
end of treatment, only 20% had mild depression (8 < score < 13);
and at the 1-month follow-up assessment, 100% already
showed a stable mood (score < 7).

Table 3 presents the comparison of HAM-D17 and
WHOQOL-BREF psychological domain scores at the 3 eval-
uation moments, separating the sample by the type of protocol
that was applied (1 Hz inhibitory and 10 Hz excitatory) and by
age groups (adults and elders).

Discussion
In this prospective case series clinical study, we aimed to evalu-
ate the effects of rTMS in the treatment of PSD and how they
affect the patient’s quality of life. Our results suggest that both
protocols, excitatory (10 Hz on F3, n = 8) and inhibitory (1 Hz
in F4, n = 7), were effective in reducing depressive symptoms in
the treatment of PSD and in the improvement of the individual’s quality of life. In both groups, there was a significant change in HAM-D and WHOQOL-BREF scores and the changes could be observed up to 1 month after the treatment with rTMS.

In our sample (n = 15), 5 patients were ≥ 65 years old and all of them responded well to the rTMS treatment regardless of the protocol, inhibitory (n = 1) and excitatory (n = 4). Compared with the group of younger adults, there were no notable differences in the way patients responded to the intervention. Previous studies have discussed the relationship between the atrophy of the frontal cortex, which is a normal process of aging in the brain, to a weaker antidepressant response to the protocol.

### Table 1. Demographic and clinical profile of the sample/type of protocol (n = 15).

| SAMPLE | TYPE OF PROTOCOL, NO. (%) | TOTAL | P VALUE* |
| --- | --- | --- | --- |
|  | F4 (46.7) | F3 (53.3) |  |
| Age (55.20 ± 12.45) |  |  |  |
| Adult | 6 (85.7) | 4 (50.0) | 10 (66.7) | .14 |
| Elder | 1 (14.3) | 4 (50.0) | 5 (33.3) |  |
| Sex |  |  |  |
| Female | 4 (57.1) | 4 (50.0) | 8 (53.3) | .78 |
| Male | 3 (42.9) | 4 (50.0) | 7 (46.7) |  |
| Marital status |  |  |  |
| With partner | 3 (42.9) | 5 (62.5) | 8 (53.3) | .45 |
| Without partner | 4 (57.1) | 3 (37.5) | 7 (46.7) |  |
| Time since stroke (y) |  |  |  |
| 7-15 | 4 (57.1) | 3 (37.5) | 7 (46.7) | .45 |
| Up to 6 | 3 (42.9) | 5 (62.5) | 8 (53.3) |  |
| Number of kids |  |  |  |
| 1-2 kids | 3 (42.9) | 6 (75.0) | 9 (60.0) | .20 |
| None | 4 (57.1) | 2 (25.0) | 6 (40.0) |  |

Abbreviations: F3, excitatory protocol; F4, inhibitory. *Pearson χ² test.
rTMS stimulation.\textsuperscript{18–20} The authors have also been discussing whether adjustments in the intensity of the stimuli would be necessary, considering this atrophy.\textsuperscript{21,22}

With age, the reduction of brain volume occurs disproportionately, affecting the frontal cortex much more than the motor cortex.\textsuperscript{23} Thus, it can be argued that the individual's MT may become a faulty reference to calculate the appropriate intensity to stimulate the frontal cortex in rTMS protocols for depression.\textsuperscript{24} Although some authors propose adjusting the stimulus intensity considering the distance between the cortex and the scalp generated by atrophy,\textsuperscript{25–27} other studies report this correlation is still inconclusive and inconsistent.\textsuperscript{24,28} Besides that, List et al\textsuperscript{29} and Sabesan et al\textsuperscript{24} noted that there may be a relationship between the lower motor cortical thickness and lower MT in older people. This indicates that, despite causing a reduction in the strength of the magnetic field that reaches the cortex, brain atrophy also increases the cortical excitability, so that even smaller intensities are enough to stimulate the brain.\textsuperscript{24,28}

Regarding the type of protocol (1 Hz inhibitory, n = 7 and 10 Hz excitatory, n = 8), patients of both groups responded similar to the intervention, when comparing their scores at each moment of assessment. The group that received the 1 Hz inhibitory protocol significantly reduced the HAM-D17 scores (from 26.00 ± 3.65 to 6.43 ± 1.90) by the end of the 20 sessions. The follow-up evaluation also indicates a continuous improvement until 1 month after the end of the treatment, when the score decreased to 4.57 ± 0.79. In practice, subjects who were either severely or very severely depressed at baseline presented with a stable mood at the end of treatment, with a slight improvement of the scores 1 month after the end of treatment. Similarly, in the group that received the 10 Hz

| STATUS                     | INTERVENTION, NO. (%) | P VALUE* |
|---------------------------|-----------------------|----------|
|                           | BASELINE | END OF TREATMENT | FOLLOW-UP |
| Stable mood               | 0 (0.0)  | 12 (80.0)        | 15 (100.0) | <.001 |
| Mild depression           | 0 (0.0)  | 3 (20.0)         | 0 (0.0)    |        |
| Severe depression         | 4 (26.7) | 0 (0.0)          | 0 (0.0)    |        |
| Very severe depression    | 11 (73.3)| 0 (0.0)          | 0 (0.0)    |        |

*χ² test.

| PROTOCOL (M ± SD) | AGE GROUP (M ± SD) |
|-------------------|--------------------|
| INHIBITORY F4 (N=7) | EXCITATORY F3 (N=8) | ADULTS (<65 Y) (N=10) | ELDERS (>65 Y) (N=5) |
| HAM-D17           |
| Baseline          | 26.00 ± 3.65a      | 23.38 ± 2.50a         | 25.10 ± 3.35a         | 23.60 ± 3.21a |
| End of treatment  | 6.43 ± 1.90b       | 4.25 ± 0.89b          | 5.60 ± 1.71b          | 4.60 ± 1.95b |
| 1-month follow-up | 4.57 ± 0.79c       | 4.13 ± 0.83b          | 4.30 ± 0.67b          | 4.40 ± 1.14b |
| Pns               | .001               | .001                 | <.001                 | .10 |

WHOQOL-BREF—psychological domain

| Baseline          | 17.86 ± 12.90a     | 37.51 ± 19.42a       | 23.75 ± 13.50a        | 37.52 ± 26.50a |
| End of treatment  | 58.94 ± 7.78b      | 67.19 ± 10.08b       | 61.67 ± 8.76b         | 66.88 ± 11.77a,b |
| 1-month follow-up | 70.23 ± 6.57c      | 73.46 ± 11.12b       | 71.25 ± 7.97c         | 73.36 ± 12.01b |
| Pns               | .001               | .001                 | <.001                 | .20 |

Abbreviations: HAM-D17, 17-item Hamilton Depression Rating Scale; F, *Friedman test; WHOQOL-BREF, World Health Organization Quality of Life-Brief Version. Different letters indicate significant differences when comparing subsequent evaluations (Wilcoxon test).
excitatory protocol (n = 8), scores decreased considerably (from 23.38 ± 2.50 to 4.25 ± 0.89) from severe or very severe depression to stable mood at the end of treatment. In the follow-up evaluation, the scores remained stable (4.13 ± 0.83), without significant change.

Our results resonate with previous findings of studies in which the rTMS high-frequency protocol over the left DLPFC improved mood of patients with stroke sequelae and of patients who had major depressive disorders (MDDs). A systematic review and meta-analysis of controlled clinical trials on the use of rTMS for the treatment of PSD analyzed 22 clinical trials with 1764 patients. Their findings indicated the improvement of the depressive condition and significant differences in HAM-D scores after the intervention, leading to the conclusion that rTMS may indeed have a positive effect on PSD treatment. Seo Gu and Chang conducted a study to verify the efficacy of the 10 Hz protocol on the left DLPFC (F3) to treat PSD and improve motor function. As a result, the authors report that rTMS was able to relieve depressive symptoms and that the results were also maintained up to 1 month after the end of treatment.

Similarly, Caultfield et al. reported 2 cases of elderly patients with a history of stroke in the left hemisphere who had a good response to the 1 Hz inhibitory protocol of rTMS over the right DLPFC (F4). One of the subjects’ 24-item Hamilton Depression Rating Scale (HAM-D-24) score decreased from 23 in the initial state to 6 after 30 rTMS session and her Beck Depression Inventory (BDI) scores decreased from 31 to 1. Although limited to 2 cases, their data resonate with our findings, suggesting that the low-frequency rTMS over the right DLPFC may also be effective in the treatment of depression in patients with left frontal stroke.

The cortical activity of the prefrontal brain regions, specifically the right and left DLPFCs, has been the subject of medical imaging studies on MDD. Studies using positron emission tomography, functional magnetic resonance imaging (fMRI), and rTMS show hypoactivity on the left DLPFC (F3) and hyperactivity on the right DLPFC (F4) in patients with MDD, supporting the hypothesis that the neuropsychological foundations of MDD can be related to an asymmetry and imbalance of the prefrontal cortical activity between both hemispheres. This understanding of the imbalance of the prefrontal cortex has guided researchers into testing rTMS with inhibitory and excitatory protocols, and their results have revealed that both choices are effective, not only for treating depression, but also for generalized anxiety disorder, aphasia, and poststroke motor sequel.

Studies in healthy individuals have shown that both cerebral hemispheres process emotions. Although the left DLPFC processes positive emotions, the right side is responsible for the negative ones. Thus, when the left DLPFC is injured, the individual develops depression. Neuroimaging studies also report that in patients with MDD, the left DLPFC hypoactivity is associated with a worse emotional judgment and the right DLPFC hyperactivity is associated with more severe depressive symptoms.

Our results also corroborate the assumptions raised by Nitschke and Mackiewicz, Gainotti, and Grimm et al. At the baseline of the group receiving the low-frequency (inhibitory) rTMS in the right DLPFC (F4), WHOQOL-BREF’s psychological domain score was much lower (17.86 ± 12.90) than the score of the group receiving the excitatory protocol (37.51 ± 19.42) in F3. In addition, the HAM-D score was higher, indicating that depressive symptoms were more pronounced in this group.

It is worth noting that, in our study, the location of the brain injury defined the protocol of rTMS to be used in the PSD treatment, applying the stimulus always in the healthy hemisphere (contralateral to the injury). Following a similar line of reasoning, previous studies of patients with stroke sequelae have shown clinical benefits from using rTMS. Olivieri et al. stimulated the healthy hemisphere of patients with hemi-spatial neglect and perceived improvements in their clinical condition; likewise, Martin et al. stimulated the healthy hemisphere of patients presenting aphasia and also reported improvement in their naming skills.

Also corroborating our data, a study conducted with the same population and same excitatory protocol compared the response of 20 patients to the treatment with the high-frequency rTMS. A total of 10 individuals received active stimulation and 10 received sham stimulation. The group that received active stimulation presented a significant difference in HAM-D and BDI scores. The same difference could not be observed in the group of patients who received sham stimulation, leading to the conclusion that the excitatory rTMS intervention could be considered effective for the treatment of PSD and that this improvement continued for at least until 1 month after the end of the intervention.

All individuals in our study responded to the treatment and achieved remission of depressive symptoms, regardless of the protocol. This is a higher rate than what other studies have previously found. In a systematic review and meta-analysis of randomized controlled clinical trials (RCT) on the use of rTMS for the treatment of PST, Shen et al analyzed 12 RCTs that reported qualified data about response rates. The authors found that 64.4% and 39.7% of subjects in the experiment or control groups were classified as responders, respectively. Eleven RCTs reported a number of 28.8% remitters of experiment groups and 30.2% of control groups. It is hard to compare our findings with the studies included in this meta-analysis, though, due to their heterogeneous samples, methodologies, and protocols.

Bucur and Papagno also conducted a recent systematic review of studies that used noninvasive brain stimulation for PSD. Of the 7 articles that were analyzed in full, only 3 studies used rTMS. Regarding their response and remission rates, (a) Jorge et al. reported that 3 out of the 10 patients that received
active rTMS were considered responders, and only 1 patient met the criteria for remission; (b) El Etribi et al reported a response rate of 60%, but no remitters; and (c) Gu and Chang did not set response or remission criteria.

Considering the aforementioned, the reasons behind the expressive response and remission rates in our study remain uncertain and inconclusive.

Limitations of the study
It is worth mentioning that our study was limited to a small sample and lacked a control or sham-rTMS group. Future clinical trials should be conducted on poststroke patients with depressive disorder, with an appropriate sample, blinding, control group, and fMRI images of the brain, to validate the efficiency of the rTMS protocols, as well as their effects in a longer-term follow-up.

Conclusions
A deeper understanding of the results that rTMS treatments can achieve may be fundamental to promote public health policies and more effective strategies and protocols for the treatment of PSD, thus improving patients’ quality of life, providing them with better assistance, and reducing their vulnerability to the impact of a neurological sequel.

The current scientific repertory lacks effective alternatives to treating PSD, as many individuals recovering from brain injuries remain resistant to pharmacologic therapy. Our brief clinical study suggests that both inhibitory and excitatory protocols of rTMS may be effective in reducing depressive symptoms in PSD and improving their quality of life, thus becoming a promising alternative to accomplish this task.

Author Contributions
HBS Jr and AMCS conceived and planned the trials. HBS Jr was the responsible for the selection and assessment of the patients with the HAM-D17 and WHOQOL-BREF. AMCS helped with the design of the study and she was also the medical doctor responsible for the application of the rTMS protocol. HBS Jr and AMCS collaborated to the interpretation of data. HBS Jr wrote the manuscript with support from MRF. All authors contributed to the final version of the manuscript, providing critical feedback and helping to shape the research. MRF supervised the project.

ORCID iD
Hercílio Barbosa da Silva Júnior https://orcid.org/0000-0003-1873-4865

REFERENCES
1. Duan X, Yao G, Liu Z, Cui R, Yang W. Mechanisms of transcranial magnetic stimulation treating on post-stroke depression. Front Hum Neurosci. 2018;12: 215-216.
2. Angelelli P, Paoletti C, Bivona U, et al. Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. Acta Psychiatr Scand. 2004;110:55-63.
3. Zhao F, Yue Y, Li L, et al. Clinical practice guidelines for post-stroke depression in China. Braz J Psychiatry. 2018;40:325-334.
4. Lensi GI, Altieri M, Maestriini I. Post-stroke depression. Rev Neurol (Paris). 2008;64:837-840.
5. Terroni L, Sobreiro FMM, Conforto AB, et al. Association among depression, cognitive impairment and executive dysfunction after stroke. Dement Neuropsychiatr. 2012;6:152-157.
6. Alajbegovic A, Djilovic-Vranic J, Nakicvic A, et al. Post stroke depression. Med Arch. 2016;68:47-50.
7. Barra M, Evensen GS, Valeberg BT. Cues and clues predicting presence of symptoms of depression in stroke survivors. J Clin Nurs. 2016;25:546-556.
8. Kim JS. Post-stroke mood and emotional disturbances: pharmacological therapy based on mechanisms. J Stroke. 2016;18:677-681.
9. Vahid-Ansari F, Lagace DC, Albert PR. Persistent post-stroke depression in mice following unilateral medial prefrontal cortical stroke. Transl Psychiatry. 2016;5:e683.
10. Horvath JC, Mathews J, Demitrack MA, Pascual-Leone A. The NeuroStar TMS device: conducting the FDA approved protocol for treatment of depression. J Vis Exp. 2010;45:2345.
11. Bucur M, Papagno C. A systematic review of noninvasive brain stimulation for post-stroke depression. J Affect Disord. 2018;238:69-78.
12. Wagner T, Valero-Cabre A, Pascual-Leone A. Noninvasive human brain stimulation. Annu Rev Biomed Eng. 2009;9:527-565.
13. Cohen H, Kaplan Z, Kotler M, Kouperman I, Moisa R, Grisaru N. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2004;161:515-524.
14. Barker AT, Jalinson R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet. 1985;1:1106-1107.
15. Wassermann EM, Zimmermann T. Transcranial magnetic brain stimulation: therapeutic promises and scientific gaps. Pharmacol Ther. 2012;133:98-107.
16. Diomio A, Duarte IC, Patricio M, Cantelo-Branco M. The use of repetitive transcranial magnetic stimulation for stroke rehabilitation: a systematic review. J Stroke Cerebrovasc Dis. 2017;27:1-31.
17. Ciobanu C, Girard M, Marin B, Labrunie A, Malauzat D. RTMS for pharmaco-resistant major depression in the clinical setting of a psychiatric hospital: Effectiveness and effect of age. J Affect Disord. 2013;150:677-681.
18. Manes F, Jorge R, Morcuende M, et al. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. Int Psychogeriatr. 2001;13:235-231.
19. Mosimann UP, Schmitt W, Greenberg BD, et al. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. Psychiatry Res. 2004;126:123-133.
20. Pallanti S, Cantisani A, Grassi G, et al. rTMS age-dependent response in treatment-resistant depressed subjects: a mini-review. CNS Spectr. 2012;17:24-30.
21. Wagner T, Eden UJ, Fregni F, et al. Transcranial magnetic stimulation and brain atrophy: a computer-based human brain model study. Exp Brain Res. 2008;186:539-550.
22. Kozel FA, Nahas Z, deBrux C, et al. How coil-cortex distance relates to age, motor threshold, and antidepressant response to repetitive transcranial magnetic stimulation. J Affect Disord. 2017;2016;6:e863.
23. McConnell KA, Nahas Z, Shastri A, et al. The transcranial magnetic stimulation motor threshold depends on the distance from coil to underlying cortex: a replication in healthy adults comparing two methods of assessing the distance to motor cortex. J Clin Neurosci. 2001;49:454-459.
24. Sabesan P, Lunkappa S, Khalifa N, et al. Transcranial magnetic stimulation for geriatric depression: promises and pitfalls. World J Psychiatry. 2017;5:170-181.
25. Nahas Z, Li X, Kozel FA, et al. Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study. Depress Anxiety. 2004;19:249-256.
26. Koecher S, Sommer J, Deppe M, Steinsrater O. Scalp position and efficacy of transcranial magnetic stimulation. Clin Neurophysiol. 2005;116:1988-1993.
27. Stokes MG, Chambers CD, Gould JC, et al. Simple metric for scaling motor threshold based on scalp-cortex distance: application to studies using transcranial magnetic stimulation. J Neurophysiol. 2005;94:4520-4527.
28. Rossini PM, Rossi S, Babiloni C, Polich J. Clinical neurophysiology of aging brain: from normal aging to neurodegeneration. Prog Neurobiol. 2007;83:375-400.
29. Lott J, Kubke JC, Lindenberg R, et al. Relationship between excitability, plasticity and thickness of the motor cortex in older adults. Neuroimage. 2013;83:809-816.
30. Shen XY, Liu MY, Cheng Y, et al. Repetitive transcranial magnetic stimulation for the treatment of post-stroke depression: a systematic review and meta-analysis of randomized controlled clinical trials. J Affect Disord. 2017;211:65-74.
31. Gu SY, Chang MC. The effects of 10-Hz repetitive transcranial magnetic stimulation on depression in chronic stroke patients. *Brain Stimul.* 2017;10: 270-274.

32. Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wierckzi TS. The clinical TMS society consensus review and treatment recommendations for TMS therapy for major depressive disorder. *Brain Stimul.* 2016;9:336-346.

33. Janicak PG, Dunner DL, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. *CNS Spectr.* 2013;18: 322-332.

34. Caulfield KA, Bernstein MH, Stern AP, Pascual-Leone A, Fox MD. Antidepressant effect of low-frequency right-sided rTMS in two patients with left frontal stroke. *Brain Stimul.* 2017;10:150-151.

35. Gershon AA, Dannon PN, Grunhaus L. Transcranial magnetic stimulation in the treatment of depression. *Am J Psychiatry.* 2003;160:835-845.

36. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. *Br Med Bull.* 2003;65:193-207.

37. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. *Biol Psychiatry.* 2003;54: 515-528.

38. Eche J, Mondino M, Haesebaert F, Saoud M, Poulet E, Brunelin J. Low- vs. high-frequency repetitive transcranial magnetic stimulation as an add-on treatment for refractory depression. *Front Psychiatry.* 2012;3:13-14.

39. Benatti B, Cremaschi L, Oldani L, De Cagna F, Visnara M, Dell’Osso B. Past, present and future of transcranial magnetic stimulation (TMS) in the treatment of psychiatric disorders. *Evid Based Psych Care.* 2016;2:77-85.

40. Ruiz ML, Sarasa MLR, Rodriguez LS, et al. Evidencias actuales sobre la estimulación magnética transcraneal y su utilidad potencial en la neurorrehabilitación postictus: Ampliando horizontes en el tratamiento de la enfermedad cerebrovascular. *Sociedade Española Neurologia.* 2016;33:1-14.

41. Nitschke JB, Mackiewicz KL. Prefrontal and anterior cingulate contributions to volition in depression. *Int Rev Neurobiol.* 2005;67:73-94.

42. Gainotti G. Emotions and the right hemisphere: can new data clarify old models? *Neuroscientist.* 2019;25:258-270.

43. Grimm S, Beck J, Schuepbach D, et al. Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. *Biol Psychiatry.* 2008;63:369-376.

44. Olivieri M, Bisiach E, Brightina F, et al. rTMS of the unaffected hemisphere transiently reduces contralesional visuospatial hemineglect. *Neurology.* 2001;57: 1338-1340.

45. Martin PI, Naeser MA, Theoret H, et al. Transcranial magnetic stimulation as a complementary treatment for aphasia. *Semin Speech Lang.* 2004;25:181-191.

46. Jorge RE, Robinson RG, Tateno A, et al. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. *Biol Psychiatry.* 2004;55:398-405.

47. El Etribi A, El Nahas N, Nagy N, Nabil H. Repetitive transcranial magnetic stimulation treatment in post stroke depression. *Curr Psychiatry.* 2010;17:9-14.